Epidemiology of bacterial infections in patients with liver cirrhosis. Experience in a Spanish tertiary health center

Katerina Klímová, Camilo Padilla, Juan Carlos Ávila, Gerardo Clemente, Alejandra Ochoa, .

Keywords: Bacterial infections/epidemiology, liver cirrhosis, drug resistance, multiple, bacterial, anti-bacterial agents, risk factors

Abstract

Introduction: Bacterial infections represent a serious complication of liver cirrhosis. Traditionally, Gram negative bacteria have been described as the microorganisms responsible for the majority of the infections. However, in the past few years, changes in the microbiological spectrum have been described, and multiresistant bacteria are observed more frequently. Objective: To assess the proportion of patients with infections caused by multiresistant bacteria admitted to our hospital, and to obtain information about their epidemiology, risk factors and clinical impact. Materials and methods: We performed a retrospective evaluation of 294 cirrhotic patients admitted to our unit due to infection between June, 2011, and June, 2013. Results: We isolated 310 microorganisms from 294 patients; 109 (35.2%) were Gram positive, 167 (53.9%), Gram negative, and 34, fungi (11%). As for the microbiological agents, the most frequent was Escherichia coli (98 isolations). The infection was community-acquired in 22.9% of cases, healthcareassociated in 38.1% and nosocomial in 39%. Worse liver infections and septic shock were more frequent among patients with multiresistant isolates (p=0.05); and intrahospital mortality was also higher among them (p=0.017). Previous hospital admission, antibiotic treatment 60 days before, nosocomial or healthcare-associated acquisition and bacterial isolation in control cultures were identified as possible risk factors for the development of multiresistant infection. Discussion: The results of our study confirm that important changes have ocurred in the microbiological spectrum of bacterial infections in patients with liver cirrhosis. Multiresistant bacteria are associated with high morbidity and mortality, as well as failure of traditional antibiotic treatment. Successfull control of the infection requires an early identification of patients at risk.

Downloads

Download data is not yet available.
  • Katerina Klímová Servicio Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Madrid, España
  • Camilo Padilla Servicio Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Madrid, España
  • Juan Carlos Ávila Servicio Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Madrid, España
  • Gerardo Clemente Servicio Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Madrid, España
  • Alejandra Ochoa Servicio Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Madrid, España

References

Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology. 2009;50:2022-33. http://dx.doi.org/10.1002/hep.23264

Jalan R, Fernández J, Wiest R, Schnabl B, Moreau R, Angeli P, et al . Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. Hepatology. 2014;60:1310-24. http://dx.doi.org/10.1016/j.jhep.2014.08.010

Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, et al . Bacterial infection in patients with advanced cirrhosis: A multicentre prospective study. Dig Liver Dis. 2001;33:41-8. http://dx.doi.org/10.1016/S1590-8658(01)80134-1

Bauer TM, Steinbruckner B, Brinkmann FE, Ditzen AK, Schwacha H, Aponte JJ, et al . Small intestinal bacterial overgrowth in patients with cirrhosis: Prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96:2962-7. http://dx.doi.org/10.1111/j.1572-0241.2001.04668

Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol. 1993;18: 353-8. http://dx.doi.org/10.1016/S0168-8278(05)80280-6

Pleguezuelo M, Benítez JM, Jurado J, Montero JL, De la Mata M. Diagnosis and management of bacterial infections in descompensated cirrhosis. World J Hepatol. 2013;5:16-25. http://dx.doi.org/10.4254/wjh.v5.i1.16

Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, et al . Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35:140-8. http://dx.doi.org/10/S0270913902984429

Fernández J, Acevedo J, Castro M, García O, Rodríguez-de Lope C, Roca D, et al . Prevalence and risk factors of infections by multiresistant bacteria in cirrosis: A prospective study. Hepatology. 2012;55:1551-61. http://dx.doi.org/10.1002/hep.25532

Tandon P, Delisle A, Topal JE, García-Tsao G. High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US Liver Center. Clin Gastroenterol Hepatol. 2012;10:1291-8. http://dx.doi.org/10.1016/j.cgh.2012.08.017

European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontanous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397-417. http://dx.doi.org/10.1016/j.jhep.2010.05.004

Mandell GL, Bennet JE, Dolin R. Principles and Practice of Infectious Diseases. 7th edition. Philadelphia, PA: Churchill Livingstone Elsevier; 2010.

Tandon P, García-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28:26-42. http://dx.doi.org/10.1055/s-2008-1040319

Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother. 2009;64(Suppl.1):i3-10. http://dx.doi.org/10.1093/jac/dkp256

Rodríguez-Baño J, Alcalá J, Cisneros JM, Grill F, Oliver A, Horcajada JP. Escherichia coli producing SHV-type extended-spectrum beta-lactamase is a significant cause of community-acquired infection. J Antimicrob Chemother. 2009;63:781-4. http://dx.doi.org/10.1093/jac/dkp028

Umgelter A, Reindl W, Miedanes M, Schmid RM, Huber W. Failure of current antibiotic first-line regimens and mortality in hospitalized patiens with spontaneous bacterial peritonitis. Infection. 2009;37:2-8. http://dx.doi.org/10.1007/s15010-008-8060-9

Rodríguez-Baño J, Pascual A. Clinical significance of extended-spectrum-beta-lactamases. Expert Rev Anti Infect Ther. 2008;6:671-83. http://dx.doi.org/10.1586/14787210.6.5.671

Martínez-Martínez L, Calvo J. El problema creciente de la resistencia antibiótica en bacilos gramnegativos: situación actual. Infecc Microbiol Clin. 2010;28(Supl.2):25-31. http://dx.doi.org/10.1016/S0213-005X(10)70027-6

Kalambokis GN, Mouzaki A, Tsianos EV. Rifaximin for the prevention of spontaneous bacterial peritonitis. World J Gastroenterol. 2012;18:1700-2. http://dx.doi.org/10.3748/wjg.v18.i14.1700

Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Fotopoulos A, Xourgia X, et al . Rifaximin improves systemic hemodynamic and renal function in patients with alcohol related cirrhosis. Clin Gastroenterol Hepatol. 2012;10:815-8. http://dx.doi.org/10.1016/j.cgh.2012.02.025

How to Cite
1.
Klímová K, Padilla C, Ávila JC, Clemente G, Ochoa A. Epidemiology of bacterial infections in patients with liver cirrhosis. Experience in a Spanish tertiary health center. biomedica [Internet]. 2016 Mar. 1 [cited 2024 May 16];36(1):121-32. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/2600

Some similar items:

Published
2016-03-01
Section
Original articles

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
Crossref Cited-by logo
QR Code